Roy Fleischmann1, Mark C Genovese2, Yong Lin3, Gregory St John4, Désirée van der Heijde5, Sheldon Wang3, Juan Jose Gomez-Reino6, Jose Antonio Maldonado-Cocco7, Marina Stanislav8, Alan J Kivitz9, Gerd R Burmester10. 1. Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX. 2. Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA. 3. Sanofi Genzyme, Bridgewater, NJ. 4. Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA. 5. Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands. 6. IDIS, Complejo Hospitalario Universitario de Santiago, Santiago, Spain. 7. School of Medicine, Buenos Aires University, Buenos Aires, Argentina. 8. Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russia. 9. Altoona Center for Clinical Research, Duncansville, PA, USA. 10. Charité - University Medicine Berlin, Berlin, Germany.
Abstract
OBJECTIVE: Sarilumab is a human monoclonal antibody that blocks IL-6 from binding to membrane-bound and soluble IL-6 receptor-α. We assessed the long-term safety of sarilumab in patients from eight clinical trials and their open-label extensions. METHODS: Data were pooled from patients with rheumatoid arthritis who received at least one dose of sarilumab in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs; combination group) or as monotherapy (monotherapy group). Treatment-emergent adverse events (AEs) and AEs and laboratory values of special interest were assessed. RESULTS: 2887 patients received sarilumab in combination with csDMARDs and 471 patients received sarilumab monotherapy, with mean exposure of 2.8 years and 1.7 years, maximum exposure 7.3 and 3.5 years, and cumulative AE observation period of 8188 and 812 patient-years, respectively. Incidence rates per 100 patient-years in the combination and monotherapy groups, respectively, were 9.4 and 6.7 for serious AEs, 3.7 and 1.0 for serious infections, 0.6 and 0.5 for herpes zoster (no cases were disseminated), 0.1 and 0 for gastrointestinal perforations, 0.5 and 0.2 for major adverse cardiovascular events, and 0.7 and 0.6 for malignancy. Absolute neutrophil counts <1000 cells/mm3 were recorded in 13% and 15% of patients, respectively. Neutropenia was not associated with increased risk of infection or serious infection. Analysis by 6-month interval showed no signal for increased rate of any AE over time. CONCLUSION: The long-term safety profile of sarilumab, either in combination with csDMARDs or as monotherapy, remained stable and consistent with the anticipated profile of a molecule that inhibits IL6 signalling.
OBJECTIVE:Sarilumab is a human monoclonal antibody that blocks IL-6 from binding to membrane-bound and soluble IL-6 receptor-α. We assessed the long-term safety of sarilumab in patients from eight clinical trials and their open-label extensions. METHODS: Data were pooled from patients with rheumatoid arthritis who received at least one dose of sarilumab in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs; combination group) or as monotherapy (monotherapy group). Treatment-emergent adverse events (AEs) and AEs and laboratory values of special interest were assessed. RESULTS: 2887 patients received sarilumab in combination with csDMARDs and 471 patients received sarilumab monotherapy, with mean exposure of 2.8 years and 1.7 years, maximum exposure 7.3 and 3.5 years, and cumulative AE observation period of 8188 and 812 patient-years, respectively. Incidence rates per 100 patient-years in the combination and monotherapy groups, respectively, were 9.4 and 6.7 for serious AEs, 3.7 and 1.0 for serious infections, 0.6 and 0.5 for herpes zoster (no cases were disseminated), 0.1 and 0 for gastrointestinal perforations, 0.5 and 0.2 for major adverse cardiovascular events, and 0.7 and 0.6 for malignancy. Absolute neutrophil counts <1000 cells/mm3 were recorded in 13% and 15% of patients, respectively. Neutropenia was not associated with increased risk of infection or serious infection. Analysis by 6-month interval showed no signal for increased rate of any AE over time. CONCLUSION: The long-term safety profile of sarilumab, either in combination with csDMARDs or as monotherapy, remained stable and consistent with the anticipated profile of a molecule that inhibits IL6 signalling.
Authors: Mark C Genovese; Roy Fleischmann; Alan Kivitz; Eun-Bong Lee; Hubert van Hoogstraten; Toshio Kimura; Gregory St John; Erin K Mangan; Gerd R Burmester Journal: Arthritis Res Ther Date: 2020-06-10 Impact factor: 5.156
Authors: Pavel Kovalenko; Anne Paccaly; Anita Boyapati; Christine Xu; Gregory St John; Michael C Nivens; John D Davis; Ronda Rippley; A Thomas DiCioccio Journal: CPT Pharmacometrics Syst Pharmacol Date: 2020-06-20
Authors: Philipp Arnold; Wiebke Lückstädt; Wenjia Li; Inga Boll; Juliane Lokau; Christoph Garbers; Ralph Lucius; Stefan Rose-John; Christoph Becker-Pauly Journal: Cells Date: 2020-05-24 Impact factor: 6.600
Authors: Anne J Paccaly; Pavel Kovalenko; Janie Parrino; Anita Boyapati; Christine Xu; Hubert van Hoogstraten; Tomonori Ishii; John D Davis; A Thomas DiCioccio Journal: J Clin Pharmacol Date: 2020-07-29 Impact factor: 3.126
Authors: Daniel Aletaha; Clifton O Bingham; George Athanasios Karpouzas; Tsutomu Takeuchi; Carter Thorne; Androniki Bili; Prasheen Agarwal; Benjamin Hsu; Ravi Rao; Kurt Brown; Yoshiya Tanaka Journal: RMD Open Date: 2021-01
Authors: Helena F Florindo; Ron Kleiner; Daniella Vaskovich-Koubi; Rita C Acúrcio; Barbara Carreira; Eilam Yeini; Galia Tiram; Yulia Liubomirski; Ronit Satchi-Fainaro Journal: Nat Nanotechnol Date: 2020-07-13 Impact factor: 40.523